Drug Profile
Research programme: infectious disease vaccines - Sanofi/CureVac/In Cell Art
Latest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator CureVac; In Cell Art
- Developer CureVac; In Cell Art; Sanofi
- Class RNA vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Infections
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for research development in Infections in Europe
- 28 Aug 2018 No recent reports of development identified for research development in Infections(Prevention) in Europe
- 09 Aug 2016 Early research development is ongoing for Infections (Treatment and Prevention) in Europe (CureVac pipeline, August 2016)